Logo image of HLN

HALEON PLC-ADR (HLN) Stock Price, Forecast & Analysis

USA - New York Stock Exchange - NYSE:HLN - US4055521003 - ADR

10.46 USD
+0.13 (+1.26%)
Last: 1/23/2026, 8:04:00 PM
10.3 USD
-0.16 (-1.53%)
After Hours: 1/23/2026, 8:04:00 PM

HLN Key Statistics, Chart & Performance

Key Statistics
Market Cap46.58B
Revenue(TTM)11.23B
Net Income(TTM)1.44B
Shares4.45B
Float4.45B
52 Week High11.42
52 Week Low8.71
Yearly Dividend0.17
Dividend Yield1.8%
EPS(TTM)0.5
PE20.92
Fwd PE18.1
Earnings (Next)02-25
IPO2022-07-18
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
HLN short term performance overview.The bars show the price performance of HLN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 2 4 6 8 10

HLN long term performance overview.The bars show the price performance of HLN in the last 1, 2 and 3 years. 1 year 2 years 3 years 5 10 15 20 25

The current stock price of HLN is 10.46 USD. In the past month the price increased by 3.46%. In the past year, price increased by 11.4%.

HALEON PLC-ADR / HLN Daily stock chart

HLN Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to HLN. When comparing the yearly performance of all stocks, HLN is one of the better performing stocks in the market, outperforming 74.18% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

HLN Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to HLN. HLN has an excellent profitability rating, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HLN Financial Highlights

Over the last trailing twelve months HLN reported a non-GAAP Earnings per Share(EPS) of 0.5. The EPS increased by 6.59% compared to the year before.


Industry RankSector Rank
PM (TTM) 12.84%
ROA 4.2%
ROE 8.92%
Debt/Equity 0.53
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%0.68%
EPS 1Y (TTM)6.59%
Revenue 1Y (TTM)-0.61%

HLN Forecast & Estimates

24 analysts have analysed HLN and the average price target is 11.78 USD. This implies a price increase of 12.62% is expected in the next year compared to the current price of 10.46.

For the next year, analysts expect an EPS growth of 5.74% and a revenue growth -1.32% for HLN


Analysts
Analysts79.17
Price Target11.78 (12.62%)
EPS Next Y5.74%
Revenue Next Year-1.32%

HLN Ownership

Ownership
Inst Owners58.32%
Ins Owners0.06%
Short Float %0.42%
Short Ratio2.04

About HLN

Company Profile

HLN logo image Haleon Plc engages in the provision of personal healthcare products. The company is headquartered in Weybridge, Surrey and currently employs 24,000 full-time employees. The company went IPO on 2022-07-18. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.

Company Info

HALEON PLC-ADR

Building 5, First Floor, The Heights

Weybridge SURREY GB

Employees: 24000

HLN Company Website

HLN Investor Relations

Phone: 441932822000

HALEON PLC-ADR / HLN FAQ

Can you describe the business of HALEON PLC-ADR?

Haleon Plc engages in the provision of personal healthcare products. The company is headquartered in Weybridge, Surrey and currently employs 24,000 full-time employees. The company went IPO on 2022-07-18. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.


Can you provide the latest stock price for HALEON PLC-ADR?

The current stock price of HLN is 10.46 USD. The price increased by 1.26% in the last trading session.


Does HALEON PLC-ADR pay dividends?

HALEON PLC-ADR (HLN) has a dividend yield of 1.8%. The yearly dividend amount is currently 0.17.


What is the ChartMill rating of HALEON PLC-ADR stock?

HLN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


On which exchange is HLN stock listed?

HLN stock is listed on the New York Stock Exchange exchange.


Can you provide the growth outlook for HALEON PLC-ADR?

The Revenue of HALEON PLC-ADR (HLN) is expected to decline by -1.32% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the Short Interest ratio of HALEON PLC-ADR (HLN) stock?

The outstanding short interest for HALEON PLC-ADR (HLN) is 0.42% of its float.